Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Versant Ventures
Deal Size : $62.0 million
Deal Type : Series A Financing
Light Horse Therapeutics Debuts with $62 Million Series A Financing
Details : The financing is intended to support the company’s discovery platform for small-molecule drug research, utilizing innovative approaches to address the underlying causes and life-threatening diseases.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 09, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Versant Ventures
Deal Size : $62.0 million
Deal Type : Series A Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $1,025.0 million
Deal Type : Collaboration
Light Horse Therapeutics Enters Into Strategic Collaboration with Novartis
Details : The collaboration between Novartis and Light Horse offers a remarkable opportunity to utilize a genetic screening platform and proprietary chemical libraries to develop innovative cancer treatments.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $25.0 million
January 09, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $1,025.0 million
Deal Type : Collaboration